C9orf72 and amyotrophic lateral sclerosis: These studies support the concept that poly-GA immunotherapy could be a viable therapeutic approach in reducing some aspects of C9orf72-linked ALS; however, given the multi-factorial disease pathogenesis of C9orf72, it is likely that treatment will require a synergistic approach when targeting downstream mechanisms.